Cancer Biomarkers Market to Reach $37.8 Billion by 2035, Growing at 4.3% CAGR | Roche, Illumina, Tempus AI Among Key Players

The global cancer biomarkers market, valued at USD 24.5 billion in 2025, will grow to USD 25.9 billion in 2026 and reach USD 37.8 billion by 2035, advancing at a compound annual growth rate of 4.3% over the forecast period. This sustained expansion reflects the healthcare industry's accelerating shift toward molecular diagnostics, precision oncology, and individualized treatment protocols across virtually every major cancer type. Investors, biopharma executives, and diagnostics manufacturers who are mapping their next decade of growth cannot afford to ignore a market at this scale and trajectory.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/cancer-biomarkers-market/request-sample.html

MARKET OVERVIEW
Cancer biomarkers are biological molecules found in blood, tissue, or other body fluids that signal the presence of cancer, track its progression, and guide treatment decisions. They sit at the intersection of diagnostics and therapeutics, serving as the molecular evidence base that allows oncologists to match patients with the therapies most likely to work. The shift from population-level treatment to patient-specific molecular profiling has made these indicators indispensable in modern oncology.

The core problem cancer biomarkers solve is the profound molecular heterogeneity of tumors. Two patients diagnosed with the same cancer type and stage can carry entirely different genetic profiles and respond very differently to the same drug. Standard pathology cannot reliably distinguish these differences; biomarker testing can. As pharmaceutical developers integrate companion diagnostics into drug approval pipelines, and as clinical guidelines increasingly require biomarker confirmation before initiating targeted or immunological therapies, demand for validated testing solutions continues to climb.

Macro forces compounding this growth include an aging global population driving cancer incidence higher, the commercial maturation of next-generation sequencing (NGS) platforms that bring high-throughput biomarker discovery within reach of regional laboratories, and rising adoption of liquid biopsy technologies that allow non-invasive, repeat testing throughout a patient's treatment journey. Major players are responding: in March 2026, Illumina entered a collaboration with Labcorp specifically to advance precision oncology testing and promote equitable access to cancer biomarker testing. In December 2025, AI-powered digital pathology company Lunit partnered with Daiichi Sankyo to accelerate biomarker discovery across two oncology pipeline programs, while Tempus AI collaborated with Whitehawk Therapeutics in October 2025 to apply its real-world dataset to biomarker-driven oncology research.

KEY GROWTH DRIVERS
Rising Global Cancer Incidence: Cancer cases are increasing worldwide, driven by aging populations, sedentary lifestyles, environmental exposures, and improving detection rates that surface previously undiagnosed disease. Each newly diagnosed patient represents a potential biomarker testing event, and as incidence rises across breast, lung, colorectal, and other cancers, so does the clinical volume that flows through diagnostic laboratories.

Technological Advancement in Sequencing and Liquid Biopsy: Next-generation sequencing has fundamentally changed the biomarker discovery process, enabling comprehensive genomic profiling that identifies tumor mutation burden (TMB), microsatellite instability (MSI), and a wide array of single nucleotide variants in a single assay. Liquid biopsy platforms are extending this capability to circulating tumor DNA in blood samples, reducing the need for invasive tissue procedures and enabling real-time monitoring of treatment response.

Pharmaceutical Investment and Companion Diagnostic Approvals: Companies such as Roche and Novartis are channeling significant capital into biomarker-driven clinical trials, effectively embedding diagnostic testing into the drug development process. Regulatory agencies including the FDA are approving companion diagnostics alongside targeted therapies, creating mandatory testing requirements that guarantee downstream diagnostic volume. Every new targeted therapy approval typically anchors demand for its associated biomarker test.

Growing Adoption of Precision Oncology Models: Health systems across North America, Europe, and Asia-Pacific are restructuring oncology care around molecular profiling. Clinicians now routinely order EGFR mutation testing before prescribing inhibitors like Osimertinib in non-small cell lung cancer, and HER2 status drives treatment decisions for both breast and gastric cancers. This institutional adoption creates durable, recurring demand rather than episodic testing volume.

MARKET SEGMENTATION
By type of biomarker, HER2 testing solutions hold the largest share at 21.1% of global revenue in 2026. This dominance stems from HER2's extensive clinical validation across breast and gastric cancers, and its direct association with high-value targeted therapies including trastuzumab and pertuzumab, which require HER2 confirmation for patient selection. Other significant biomarker segments include MET, EGFR, PD-L1, NTRK, and ALK. Among these, EGFR is the fastest-growing segment, reflecting the rising global prevalence of lung cancer and the widening clinical use of EGFR inhibitors that require mutation testing before therapy initiation.

By cancer type, breast cancer testing commands 25.1% of market revenue, driven by its status as a leading cause of cancer-related deaths in women and the well-established role of multiple biomarkers in guiding risk prediction, prognosis, and treatment selection. Melanoma testing represents the fastest-growing application segment at a projected CAGR of 4.5%, propelled by rising global melanoma incidence, the increasing use of BRAF and MEK inhibitor regimens, and expanding adoption of liquid biopsy-based biomarker platforms for this indication.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/cancer-biomarkers-market/request-quote.html

REGIONAL INSIGHTS
North America holds the commanding position in the cancer biomarkers market, accounting for 52.1% of global revenue in 2026. Several structural factors sustain this leadership: a high concentration of domestic manufacturing facilities for diagnostic reagents and sequencing instruments, an advanced healthcare infrastructure that integrates molecular diagnostics into standard oncology workflows, and strong institutional focus on personalized medicine. U.S. regulatory frameworks have historically moved quickly to approve companion diagnostics, creating a policy environment that rewards biomarker investment.

Europe represents the second-largest regional market, supported by public health funding for cancer screening programs, active clinical research networks, and regulatory harmonization through EMA frameworks. The Asia-Pacific region presents the most dynamic medium-term opportunity, with rising cancer burden across China, India, and Southeast Asia, expanding diagnostic laboratory infrastructure, and growing government investment in genomic medicine programs. As sequencing costs fall and regional laboratory capacity grows, Asia-Pacific is set to be among the fastest-growing regions through 2035.

COMPETITIVE LANDSCAPE
The cancer biomarkers market features a broad competitive field including ARUP Laboratories, Asper Biogene, BioReference, Caris Life Sciences, CeGaT, Foundation Medicine, Genekor Medical, Guardant Health, IQVIA Laboratories, Labcorp, MedGenome, NeoGenomics Laboratories, Nonacus, OncoDNA, Quest Diagnostics, Oxford Gene Technology, Personal Genome Diagnostics, PhenoPath, Positive Biosciences, Tempus, Thermo Fisher Scientific, and YuceBio, among others.

The competitive dynamic in this space combines scale-driven consolidation among laboratory service giants such as Labcorp and Quest Diagnostics with rapid disruption from AI-powered and liquid biopsy-focused specialists like Guardant Health and Tempus. The primary battlegrounds are proprietary biomarker panels, data network effects from large real-world genomic databases, and speed of companion diagnostic co-development with pharmaceutical partners. Companies that can demonstrate clinical utility across multiple cancer indications, while managing turnaround times and reimbursement pathways, hold the clearest path to sustained market share.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/cancer-biomarkers-market/253.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.